Literature DB >> 10508017

Phenotypic and genetic characterization of thymidine kinase from clinical strains of varicella-zoster virus resistant to acyclovir.

F Morfin1, D Thouvenot, M De Turenne-Tessier, B Lina, M Aymard, T Ooka.   

Abstract

Varicella-zoster virus (VZV) is a common herpesvirus responsible for disseminated or chronic infections in immunocompromised patients. Effective drugs such as acyclovir (ACV), famciclovir (prodrug of penciclovir), and foscarnet are available to treat these infections. Here we report the phenotypic and genetic characterization of four ACV-resistant VZV strains isolated from AIDS patients and transplant recipients. Sensitivity to six antiviral drugs was determined by an enzyme-linked immunosorbent assay, viral thymidine kinase (TK) activity was measured by comparing [(3)H]thymidine and 1-beta-D-arabinofuranosyl-[(3)H]thymine as substrates, and the TK gene open reading frame was sequenced. Three strains were found to be TK deficient, and the fourth was a mixed population composed of TK-positive and TK-deficient viruses. Each strain presented a unique TK gene mutation that could account for ACV resistance. In one strain, the deletion of two nucleotides at codon 215 induced a premature stop signal at codon 217. In another strain, a single nucleotide addition at codon 167 resulted in a premature stop signal at codon 206. In both other strains, we identified amino acid substitutions already described in other ACV-resistant VZV strains: either Glu-->Gly at residue 48 or Arg-->Gly at residue 143. According to our work and data previously reported on resistant VZV strains, there are three areas in the TK gene where 71% of the mutations described to date are located. These areas are putative candidates for a genotypic diagnosis of ACV resistance.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10508017      PMCID: PMC89493          DOI: 10.1128/AAC.43.10.2412

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  28 in total

1.  Nucleotide sequence changes in thymidine kinase gene of herpes simplex virus type 2 clones from an isolate of a patient treated with acyclovir.

Authors:  S Kit; M Sheppard; H Ichimura; S Nusinoff-Lehrman; M N Ellis; J A Fyfe; H Otsuka
Journal:  Antimicrob Agents Chemother       Date:  1987-10       Impact factor: 5.191

2.  Phenotypic and genotypic characterization of acyclovir-resistant herpes simplex viruses from immunocompromised patients.

Authors:  A Gaudreau; E Hill; H H Balfour; A Erice; G Boivin
Journal:  J Infect Dis       Date:  1998-08       Impact factor: 5.226

3.  Evidence that the 'active centre' of the herpes simplex virus thymidine kinase involves an interaction between three distinct regions of the polypeptide.

Authors:  D Graham; B A Larder; M M Inglis
Journal:  J Gen Virol       Date:  1986-04       Impact factor: 3.891

4.  A novel selective broad-spectrum anti-DNA virus agent.

Authors:  E De Clercq; A Holý; I Rosenberg; T Sakuma; J Balzarini; P C Maudgal
Journal:  Nature       Date:  1986 Oct 2-8       Impact factor: 49.962

5.  Thymidine kinase with altered substrate specificity of acyclovir resistant varicella-zoster virus.

Authors:  K Shiraki; T Ogino; K Yamanishi; M Takahashi
Journal:  Biken J       Date:  1986-03

6.  A rapid and automated colorimetric assay for evaluating the sensitivity of herpes simplex strains to antiviral drugs.

Authors:  M Langlois; J P Allard; F Nugier; M Aymard
Journal:  J Biol Stand       Date:  1986-07

7.  The complete DNA sequence of varicella-zoster virus.

Authors:  A J Davison; J E Scott
Journal:  J Gen Virol       Date:  1986-09       Impact factor: 3.891

8.  Molecular analysis of the pyrimidine deoxyribonucleoside kinase gene of wild-type and acyclovir-resistant strains of varicella-zoster virus.

Authors:  M H Sawyer; G Inchauspe; K K Biron; D J Waters; S E Straus; J M Ostrove
Journal:  J Gen Virol       Date:  1988-10       Impact factor: 3.891

9.  Acyclovir therapy for acute herpes zoster.

Authors:  B Bean; C Braun; H H Balfour
Journal:  Lancet       Date:  1982-07-17       Impact factor: 79.321

10.  Continuous varicella-zoster infection associated with acyclovir resistance in a child with AIDS.

Authors:  S Pahwa; K Biron; W Lim; P Swenson; M H Kaplan; N Sadick; R Pahwa
Journal:  JAMA       Date:  1988-11-18       Impact factor: 56.272

View more
  15 in total

1.  Generation of a reporter cell line for detection of infectious varicella-zoster virus and its application to antiviral studies.

Authors:  Guan-Qing Wang; Tatsuo Suzutani; Yumiko Yamamoto; Yoshiko Fukui; Naoki Nozawa; D Scott Schmid; Ichiro Kurane; Naoki Inoue
Journal:  Antimicrob Agents Chemother       Date:  2006-09       Impact factor: 5.191

2.  Herpes simplex virus thymidine kinase mutations associated with resistance to acyclovir: a site-directed mutagenesis study.

Authors:  E Frobert; T Ooka; J C Cortay; B Lina; D Thouvenot; F Morfin
Journal:  Antimicrob Agents Chemother       Date:  2005-03       Impact factor: 5.191

3.  Differences in the Likelihood of Acyclovir Resistance-Associated Mutations in the Thymidine Kinase Genes of Herpes Simplex Virus 1 and Varicella-Zoster Virus.

Authors:  Hikaru Fujii; Shizuko Harada; Tomoki Yoshikawa; Souichi Yamada; Natsumi Omura; Miho Shibamura; Takuya Inagaki; Hirofumi Kato; Shuetsu Fukushi; Masayuki Saijo
Journal:  Antimicrob Agents Chemother       Date:  2019-04-25       Impact factor: 5.191

4.  Disseminated, persistent, and fatal infection due to the vaccine strain of varicella-zoster virus in an adult following stem cell transplantation.

Authors:  Preeti Bhalla; Graeme N Forrest; Michael Gershon; Yan Zhou; Jason Chen; Philip LaRussa; Sharon Steinberg; Anne A Gershon
Journal:  Clin Infect Dis       Date:  2014-12-01       Impact factor: 9.079

5.  In vitro-selected drug-resistant varicella-zoster virus mutants in the thymidine kinase and DNA polymerase genes yield novel phenotype-genotype associations and highlight differences between antiherpesvirus drugs.

Authors:  G Andrei; D Topalis; P Fiten; C McGuigan; J Balzarini; G Opdenakker; R Snoeck
Journal:  J Virol       Date:  2011-12-21       Impact factor: 5.103

Review 6.  Antiviral drug resistance: mechanisms and clinical implications.

Authors:  Lynne Strasfeld; Sunwen Chou
Journal:  Infect Dis Clin North Am       Date:  2010-06       Impact factor: 5.982

Review 7.  Valaciclovir: a review of its use in the management of herpes zoster.

Authors:  D Ormrod; K Goa
Journal:  Drugs       Date:  2000-06       Impact factor: 9.546

8.  A rapid phenotypic assay for detection of acyclovir-resistant varicella-zoster virus with mutations in the thymidine kinase open reading frame.

Authors:  R Sahli; G Andrei; C Estrade; R Snoeck; P R Meylan
Journal:  Antimicrob Agents Chemother       Date:  2000-04       Impact factor: 5.191

9.  Complete DNA sequence analyses of the first two varicella-zoster virus glycoprotein E (D150N) mutant viruses found in North America: evolution of genotypes with an accelerated cell spread phenotype.

Authors:  Charles Grose; Shaun Tyler; Geoff Peters; Joanne Hiebert; Gwen M Stephens; William T Ruyechan; Wallen Jackson; Johnathan Storlie; Graham A Tipples
Journal:  J Virol       Date:  2004-07       Impact factor: 5.103

10.  In vitro replication of varicella-zoster virus in human retinal pigment epithelial cells.

Authors:  Jonas Schmidt-Chanasit; Karoline Bleymehl; Holger F Rabenau; Rainer G Ulrich; Jindrich Cinatl; Hans Wilhelm Doerr
Journal:  J Clin Microbiol       Date:  2008-04-09       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.